In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...

H.C. Wainwright raised the firm’s price target on Bicara Therapeutics (BCAX) to $45 from $42 and keeps a Buy rating on the shares after the ...

Bicara Therapeutics has a fifty-two week low of $11.51 and a fifty-two week high of $28.09. Bicara Therapeutics ( NASDAQ:BCAX – Get Free Report ) last issued its quarterly earnings data on ...

BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session ...

Bicara Therapeutics Inc., a company dedicated to innovative therapies, made public its intent to furnish a corporate presentation on January 13, 2025. The presentation, as detailed in its Form 8-K ...

Cantor Fitzgerald began coverage on shares of Bicara Therapeutics Inc (NASDAQ:BCAX), assigning an Overweight rating to the biopharmaceutical company. The firm highlighted the... On Tuesday, Bicara ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...